Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | n/a | 35.1 | 38.45 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Molecule Group plc, formerly Vulcan Two Group plc, is a United Kingdom-based company. The Company is focused on building a regulated ePharmacy platform through its buy-and-build. The Company has a diversified platform spanning business-to-business (B2B) prescription fulfillment and (B2C) digital pharmacy services. Its B2B platform is Molecule CloudRx, which is a regulated digital end-to-end prescription platform and B2B2C dispensing pharmacy, powered by a proprietary technology stack. Its B2C platforms are Molecule Clinic, Molecule through its own consumer-facing website. The Molecule Veterinary is a regulated Pharmacy, and Molecule Veterinary. The Molecule Clinic is a regulated B2C online clinic that prescribes and distributes weight loss and other lifestyle medications through a consumer-facing online consulting platform. Molecule Pharmacy is an over the counter (OTC) pharmacy offered and distributed digital pharmacy, dispensing and distributing private veterinary medications.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- August 6th, 2025
- Public Since
- September 3rd, 2025
- Sector
- Investment Banking & Investment Services
- Industry
- Financials
- Exchange
London Stock Exchange- Shares in Issue
- 27,275,000
- Address
- 71-75 Shelton Street, LONDON, WC2H 9JQ
- Web
- https://vulcantwo.com
- Phone
- Auditors
- HaysMac LLP
Latest News for MOL
Similar to MOL
3i
London Stock Exchange
Aberdeen
London Stock Exchange
Achilles Investment
London Stock Exchange
Reabold Resources
London Stock Exchange
Agronomics
London Stock Exchange
FAQ
As of Today at 04:10 UTC, shares in Molecule are trading at 209.00p. This share price information is delayed by 15 minutes.
Shares in Molecule last closed at 209.00p and the price had moved by -15.92% over the past 365 days. In terms of relative price strength the Molecule share price has underperformed the FTSE All Share Index by -27.44% over the past year.
The overall consensus recommendation for Molecule is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreMolecule does not currently pay a dividend.
Molecule does not currently pay a dividend.
Molecule does not currently pay a dividend.
To buy shares in Molecule you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 209.00p, shares in Molecule had a market capitalisation of £57.00m.
Here are the trading details for Molecule:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: MOL
Based on an overall assessment of its quality, value and momentum Molecule is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Molecule is 308.00p. That is 47.37% above the last closing price of 209.00p.
Analysts covering Molecule currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Molecule. Over the past six months, its share price has underperformed the FTSE All Share Index by -8.74%.
As of the last closing price of 209.00p, shares in Molecule were trading -10.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Molecule PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 209.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Molecule's directors